PL4125842T3 - Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów - Google Patents
Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworówInfo
- Publication number
- PL4125842T3 PL4125842T3 PL21721706.6T PL21721706T PL4125842T3 PL 4125842 T3 PL4125842 T3 PL 4125842T3 PL 21721706 T PL21721706 T PL 21721706T PL 4125842 T3 PL4125842 T3 PL 4125842T3
- Authority
- PL
- Poland
- Prior art keywords
- mirdametinib
- lifirafenib
- administration
- treating cancers
- cancers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005153P | 2020-04-03 | 2020-04-03 | |
| PCT/US2021/025551 WO2021202981A1 (en) | 2020-04-03 | 2021-04-02 | Co-administration of mirdametinib and lifirafenib for use in treating cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4125842T3 true PL4125842T3 (pl) | 2024-10-14 |
Family
ID=75674969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21721706.6T PL4125842T3 (pl) | 2020-04-03 | 2021-04-02 | Równoczesne podawanie mirdametynibu i lifirafenibu do stosowania w leczeniu nowotworów |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20230128315A1 (pl) |
| EP (1) | EP4125842B1 (pl) |
| JP (2) | JP7748386B2 (pl) |
| KR (1) | KR20230048476A (pl) |
| CN (1) | CN116194095B (pl) |
| AU (1) | AU2021246141A1 (pl) |
| BR (1) | BR112022019914A2 (pl) |
| CA (1) | CA3174223A1 (pl) |
| CL (1) | CL2022002682A1 (pl) |
| CO (1) | CO2022015891A2 (pl) |
| DK (1) | DK4125842T3 (pl) |
| ES (1) | ES2985012T3 (pl) |
| FI (1) | FI4125842T3 (pl) |
| HU (1) | HUE067894T2 (pl) |
| IL (1) | IL296878A (pl) |
| MX (1) | MX2022012351A (pl) |
| PE (1) | PE20231211A1 (pl) |
| PL (1) | PL4125842T3 (pl) |
| PT (1) | PT4125842T (pl) |
| TW (1) | TWI893097B (pl) |
| WO (1) | WO2021202981A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025508195A (ja) * | 2022-03-17 | 2025-03-21 | スプリングワークス、セラピューティクス、インコーポレイテッド | 小児患者における神経線維腫症１型（ｎｆ１）に関連する叢状神経線維腫（ｐｎ）のミルダメチニブによる治療 |
| US20230293464A1 (en) * | 2022-03-17 | 2023-09-21 | SpringWorks Therapeutics Inc. | Treatment of pancreatic ductal adenocarcinoma with mirdametinib |
| WO2023209611A1 (en) * | 2022-04-26 | 2023-11-02 | Beigene Switzerland Gmbh | Methods of treating cancer with a b-raf inhibitor, in particular lifirafenib |
| US20240122881A1 (en) * | 2022-10-14 | 2024-04-18 | Springworks Therapeutics, Inc. | Combination for use in treating cancers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140022053A (ko) * | 2011-04-01 | 2014-02-21 | 제넨테크, 인크. | Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법 |
| US10351559B2 (en) | 2015-04-15 | 2019-07-16 | Beigene, Ltd. | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
| WO2019113345A1 (en) * | 2017-12-06 | 2019-06-13 | Spyro Mousses | Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases |
| EP3560516A1 (en) * | 2018-04-27 | 2019-10-30 | Bergen Teknologioverforing AS | Combination therapy including beta-sitosterol in combination with at least one of a braf inhibitor, a mek inhibitor or an erk inhibitor and methods and use thereof |
-
2021
- 2021-04-02 PT PT217217066T patent/PT4125842T/pt unknown
- 2021-04-02 ES ES21721706T patent/ES2985012T3/es active Active
- 2021-04-02 PL PL21721706.6T patent/PL4125842T3/pl unknown
- 2021-04-02 CA CA3174223A patent/CA3174223A1/en active Pending
- 2021-04-02 TW TW110112271A patent/TWI893097B/zh active
- 2021-04-02 JP JP2022560245A patent/JP7748386B2/ja active Active
- 2021-04-02 FI FIEP21721706.6T patent/FI4125842T3/fi active
- 2021-04-02 HU HUE21721706A patent/HUE067894T2/hu unknown
- 2021-04-02 DK DK21721706.6T patent/DK4125842T3/da active
- 2021-04-02 CN CN202180036587.XA patent/CN116194095B/zh active Active
- 2021-04-02 US US17/995,002 patent/US20230128315A1/en active Pending
- 2021-04-02 WO PCT/US2021/025551 patent/WO2021202981A1/en not_active Ceased
- 2021-04-02 IL IL296878A patent/IL296878A/en unknown
- 2021-04-02 MX MX2022012351A patent/MX2022012351A/es unknown
- 2021-04-02 KR KR1020227038490A patent/KR20230048476A/ko active Pending
- 2021-04-02 BR BR112022019914A patent/BR112022019914A2/pt unknown
- 2021-04-02 PE PE2022002181A patent/PE20231211A1/es unknown
- 2021-04-02 AU AU2021246141A patent/AU2021246141A1/en active Pending
- 2021-04-02 EP EP21721706.6A patent/EP4125842B1/en active Active
-
2022
- 2022-09-30 CL CL2022002682A patent/CL2022002682A1/es unknown
- 2022-11-03 CO CONC2022/0015891A patent/CO2022015891A2/es unknown
-
2025
- 2025-06-18 JP JP2025102055A patent/JP2025120501A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023521036A (ja) | 2023-05-23 |
| JP7748386B2 (ja) | 2025-10-02 |
| MX2022012351A (es) | 2023-03-13 |
| ES2985012T3 (es) | 2024-11-04 |
| WO2021202981A1 (en) | 2021-10-07 |
| EP4125842A1 (en) | 2023-02-08 |
| PT4125842T (pt) | 2024-08-06 |
| US20230128315A1 (en) | 2023-04-27 |
| TWI893097B (zh) | 2025-08-11 |
| CN116194095B (zh) | 2024-09-13 |
| IL296878A (en) | 2022-12-01 |
| CA3174223A1 (en) | 2021-10-07 |
| CO2022015891A2 (es) | 2023-05-08 |
| AU2021246141A1 (en) | 2022-12-01 |
| CN116194095A (zh) | 2023-05-30 |
| CL2022002682A1 (es) | 2023-06-16 |
| BR112022019914A2 (pt) | 2022-12-13 |
| TW202207910A (zh) | 2022-03-01 |
| HUE067894T2 (hu) | 2024-11-28 |
| JP2025120501A (ja) | 2025-08-15 |
| FI4125842T3 (fi) | 2024-08-06 |
| KR20230048476A (ko) | 2023-04-11 |
| PE20231211A1 (es) | 2023-08-17 |
| EP4125842B1 (en) | 2024-06-05 |
| DK4125842T3 (da) | 2024-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE067894T2 (hu) | Mirdametinib és lifirafenib együttes beadása rákos megbetegedések kezelésében történõ alkalmazásra | |
| PT4181920T (pt) | Inibidor de kat6 e combinações para o tratamento do cancro da mama | |
| IL300067A (en) | Preparations and methods for the treatment of cancers | |
| IL277665A (en) | Heterocyclic inhibitors of MAT2A and methods of use for cancer therapy | |
| IL314346A (en) | Antibodies antagonistic to IL-18BP and their use in monotherapy and combination therapy in cancer treatment | |
| IL299950A (en) | Superantigen conjugate for use in methods and compositions for the treatment of cancer | |
| IL295088B2 (en) | Compounds and preparations for use in the treatment of skin disorders | |
| ZA202307970B (en) | Compounds for use in the treatment and prevention of covid- 19 | |
| IL319269A (en) | Combination of DCC-3116 and MAPKAP pathway inhibitors for use in cancer treatment | |
| GB202014736D0 (en) | Novel compounds and their use in therapy | |
| GB202314118D0 (en) | Methods of classifying and treating patients | |
| EP4445914A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS AND USE | |
| IL321393A (en) | CTPS1 inhibitors for use in the treatment of cancers with CTPS2 deficiency | |
| SI4340842T1 (sl) | Sotorasib za uporabo pri zdravljenju raka | |
| IL285171B2 (en) | Treatment of skin lesions and itching in patients with PRURIGO NODULARIS | |
| IL314316A (en) | Compounds and their use in cancer treatment | |
| HUE070513T2 (hu) | Rákos megbetegedések szekvenciális kezelése 6-tio-DG és checkpoint-inhibitorok alkalmazásával | |
| PL4294395T3 (pl) | Leczenie raka sutka za pomocą terapii skojarzonych zawierających GDC-9545 i GDC-0077 | |
| IL299039A (en) | Methods and preparations for the treatment of triple-negative breast cancer | |
| IL319234A (en) | Pyrazolylsulfonamide compounds and their use in therapy | |
| EP4422547A4 (en) | DEVICES AND METHODS FOR THE TREATMENT OF ORAL TISSUE | |
| IL313763A (en) | Antibodies against SARS-CoV-2 SPIKE (S) and their use in the treatment of COVID-19 | |
| GB202101728D0 (en) | Compounds and their use treating cancer | |
| IL286699A (en) | Atypical protein c kinase inhibitors and their use in the treatment of hedgehog pathway-dependent cancers | |
| CA3277801A1 (en) | Foxm1 inhibitors and their use in treating cancers |